- Email: [email protected]
5000952 Polypeptide pertussis toxin vaccine
Comp. Immun. Microbiol. infect. Dis. Vol. 15, No. 4, pp. i.--xvi, 1992 Pergamon Press Ltd. Printed in Great Britain
NEW PATENTS This section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent application filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the PATSEARCHk online database in accordance with interest profiles developed by the Editors. Further information about online patent searchingcan be obtained from Research on Demand, Inc., 2421 Fourth Street, Ste. C., Berkeley, CA 94710, U.S.A. [Tel. 510-841 1145; Fax 510-841 631 I].
4997913
5000952
PH-SENSITIVE IMMUNOCONJUGATES AND M E T H O D S F O R T H E I R U S E IN TUMOR THERAPY
POLYPEPTIDE PERTUSSIS TOXIN VACCINE
Karl E Hellstrom, Ingegerd E Hellstrom, Efraim Lavie assigned to Oncogen Novel pH-sensitive immunoconjugates which dissociate in Iow-pH tumor tissue, comprising a chemotherapeutic agent and an antibody reactive with a tumor-associated antigen are described. The chemotherapeutic agent is coupled to the antibody by a link which is unstable in low pH. The link may comprise a spacer consisting of a polyamino acid. Representative antibodies for use in these immunoconjugates include monoclonal antibodies which are not internalized by tumor cells.
5000951 MULTIVALENT CANINE DISTEMPER VIRUS VACCINE Edmund P Bass, William H Kelsey assigned to Diamond Scientific Company
Lawrence Steinman, Jorge R Oksenberg, Gary K Schoolnik, Amrit Judd assigned to The Board of Trustees of the Leland Stanford Jr University A novel method of defining oligopeptides is provided for determining useful immunodominant sequences for use as vaccines for pathogens. The method involves identifying sequences by particular selection procedures and using such sequences with antigen-presenting cells and Tcells to demonstrate activation of the common histocompatibility antigens DQ and DR in humans and their analogs in other animals. The oligopeptides may then be used individuallyor in combination to produce safe and effective vaccines, where genes may be prepared encoding the oligopeptides and used for expression of the oligopeptides or combinations of the oligopeptides or the gene transformed into the appropriate host, e.g., B. pertussis, for use as a vaccine to the intact organism.
5006341 PROTECTION
A vaccine composition for animals susceptible to infection by canine distemper virus. The vaccine comprises a small but immunologically effective amount of an inactivated canine distemper virus in combination with a non-toxic pharmaceutically acceptable immunologic adjuvant. A preferred method of inactivation of canine distemper virus by either exposure of the virus to an inactivating effective amount of binary ethyleneimine or alternatively exposure of the virus to long wavelength ultraviolet light in the presence of a furocoumarin.
Paul J Davis, Simon C Quarmby, Albert W Schoenmakers, Bedfordshire. United Kingdom assigned to Unilever Patent Holdings B V A composition useful in oral immunisation of animals such as poultry comprises dry freeflowing particles each consisting of a solid beadlet of lipid-continuousemulsion containing from about 25% to about 50% by weight water in a lipid, such as hardened palm kernel oil, having a slip point in the range 35 degrees to 45 degrees
NEW PATENTS This section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent application filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the PATSEARCHk online database in accordance with interest profiles developed by the Editors. Further information about online patent searchingcan be obtained from Research on Demand, Inc., 2421 Fourth Street, Ste. C., Berkeley, CA 94710, U.S.A. [Tel. 510-841 1145; Fax 510-841 631 I].
4997913
5000952
PH-SENSITIVE IMMUNOCONJUGATES AND M E T H O D S F O R T H E I R U S E IN TUMOR THERAPY
POLYPEPTIDE PERTUSSIS TOXIN VACCINE
Karl E Hellstrom, Ingegerd E Hellstrom, Efraim Lavie assigned to Oncogen Novel pH-sensitive immunoconjugates which dissociate in Iow-pH tumor tissue, comprising a chemotherapeutic agent and an antibody reactive with a tumor-associated antigen are described. The chemotherapeutic agent is coupled to the antibody by a link which is unstable in low pH. The link may comprise a spacer consisting of a polyamino acid. Representative antibodies for use in these immunoconjugates include monoclonal antibodies which are not internalized by tumor cells.
5000951 MULTIVALENT CANINE DISTEMPER VIRUS VACCINE Edmund P Bass, William H Kelsey assigned to Diamond Scientific Company
Lawrence Steinman, Jorge R Oksenberg, Gary K Schoolnik, Amrit Judd assigned to The Board of Trustees of the Leland Stanford Jr University A novel method of defining oligopeptides is provided for determining useful immunodominant sequences for use as vaccines for pathogens. The method involves identifying sequences by particular selection procedures and using such sequences with antigen-presenting cells and Tcells to demonstrate activation of the common histocompatibility antigens DQ and DR in humans and their analogs in other animals. The oligopeptides may then be used individuallyor in combination to produce safe and effective vaccines, where genes may be prepared encoding the oligopeptides and used for expression of the oligopeptides or combinations of the oligopeptides or the gene transformed into the appropriate host, e.g., B. pertussis, for use as a vaccine to the intact organism.
5006341 PROTECTION
A vaccine composition for animals susceptible to infection by canine distemper virus. The vaccine comprises a small but immunologically effective amount of an inactivated canine distemper virus in combination with a non-toxic pharmaceutically acceptable immunologic adjuvant. A preferred method of inactivation of canine distemper virus by either exposure of the virus to an inactivating effective amount of binary ethyleneimine or alternatively exposure of the virus to long wavelength ultraviolet light in the presence of a furocoumarin.
Paul J Davis, Simon C Quarmby, Albert W Schoenmakers, Bedfordshire. United Kingdom assigned to Unilever Patent Holdings B V A composition useful in oral immunisation of animals such as poultry comprises dry freeflowing particles each consisting of a solid beadlet of lipid-continuousemulsion containing from about 25% to about 50% by weight water in a lipid, such as hardened palm kernel oil, having a slip point in the range 35 degrees to 45 degrees